What is the Etrasimod?

Etrasimod is , while it's Molecular Formula is C26H26F3NO3.

What is the CAS number for Etrasimod?

The CAS number of Etrasimod is 1206123-37-6.

What is the Etrasimod?

Etrasimod is , while it's Molecular Formula is C26H26F3NO3.

What is the CAS number for Etrasimod?

The CAS number of Etrasimod is 1206123-37-6.

Product Class

1206123-37-6

Product Name：Etrasimod
Molecular Formula：C26H26F3NO3
Purity：99%
Molecular Weight：457.493

Inquiry

Product Details:

CasNo： 1206123-37-6

Molecular Formula： C26H26F3NO3

Factory Supply High Purity Etrasimod ,Offer 1206123-37-6 Cheapest Price

Molecular Formula:C26H26F3NO3
Molecular Weight:457.493
Boiling Point:621.4±50.0 °C(Predicted)
PKA:4.61±0.10(Predicted)
PSA：62.32000
Density:1.326±0.06 g/cm3(Predicted)
LogP:6.92780

Etrasimod(Cas 1206123-37-6) Usage

Description

Etrasimod is a selective sphingosine-1-phosphate (S1P) receptor modulator, available in oral tablet form. It belongs to the class of medications known as sphingosine 1-phosphate receptor modulators, which act on the immune system to modify its activity. By selectively binding to S1P receptor subtypes 1, 4, and 5, etrasimod modifies immune system activity, addressing inflammation and symptoms associated with ulcerative colitis.

Uses

Etrasimod is indicated for the treatment of moderate to severe active ulcerative colitis, a condition characterized by inflammation and sores in the colon and rectum. It is prescribed for adults who have not responded adequately to other therapies for ulcerative colitis. Etrasimod provides an option for individuals with this condition to manage symptoms effectively and improve quality of life.

1206123-37-6 Relevant articles

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

WJ Sandborn，S Vermeire，L Peyrin-Biroulet，MC Dubinsky，J Panes，A Yarur，T Ritter，F Baert，S Schreiber，S Sloan

The Lancet, 2023

In two independent randomised, multicentre, double-blind, placebo-controlled, phase 3 trials, ELEVATE UC 52 and ELEVATE UC 12, adults with active moderate-to-severe ulcerative colitis and an inadequate or loss of response or intolerance to at least one approved ulcerative colitis therapy were randomly assigned (2:1) to once-daily oral etrasimod 2 mg or placebo. Patients in ELEVATE UC 52 were enrolled from 315 centres in 40 countries.

Discovery of APD334: Design of a clinical stage functional antagonist of the sphingosine-1-phosphate-1 receptor

Buzard, Daniel J.,Kim, Sun Hee,Lopez, Luis,Kawasaki, Andrew,Zhu, Xiuwen,Moody, Jeanne,Thoresen, Lars,Calderon, Imelda,Ullman, Brett,Han, Sangdon,Lehmann, Juerg,Gharbaoui, Tawfik,Sengupta, Dipanjan,Calvano, Lorene,Montalban, Antonio Garrido,Ma, You-An,Sage, Carleton,Gao, Yinghong,Semple, Graeme,Edwards, Jeff,Barden, Jeremy,Morgan, Michael,Chen, Weichao,Usmani, Khawja,Chen, Chuan,Sadeque, Abu,Christopher, Ronald J.,Thatte, Jayant,Fu, Lixia,Solomon, Michelle,Mills, David,Whelan, Kevin,Al-Shamma, Hussien,Gatlin, Joel,Le, Minh,Gaidarov, Ibragim,Anthony, Todd,Unett, David J.,Blackburn, Anthony,Rueter, Jaimie,Stirn, Scott,Behan, Dominic P.,Jones, Robert M.

, p. 1313 - 1317 (2015/01/09)

APD334 was discovered as part of our int...

A Randomized, Double-Blind, Placebo-Controlled Trial of a Selective, Oral Sphingosine 1-Phosphate (S1P) Receptor Modulator, Etrasimod (APD334), in Moderate to Severe Ulcerative Colitis (UC): Results From the OASIS Study: ACG Auxiliary Award (Member) 569

Sandborn, William J. MD, FACG1; Peyrin-Biroulet, Laurent MD, PhD2; Trokan, Luba3; Zhang, Jinkun3; Kühbacher, Tanja MD, PhD4; Chiorean, Michael MD5; Lee, Scott D. MD6; Vermeire, Severine MD, PhD7; Yacyshyn, Bruce MD, FACG8; Naik, Snehal3; Klassen, Preston3; Panes, Julian PhD9

, American Journal of Gastroenterology 113():p S327-S328, October 2018.

This randomized, double-blind, parallel-group, 12-week (wk) phase 2 induction study evaluated etrasimod in pts with moderate-severe UC, defined as 3-component Mayo Clinic Score (MCS) of 4-9 with endoscopic subscore ≥2 and rectal bleeding (RB) subscore ≥1. The 3-component MCS (range 0-9) includes RB, stool frequency, and endoscopy.

1206123-37-6 Process route

: 1206124-34-6
(R/S)-ethyl 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate

: 1206123-37-6
[(3R)-7-{[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy}-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid

Conditions

Conditions	Yield
(R/S)-ethyl 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate; With water; recombinant yeast Lipase B Candida antarctica immobilized on Immobead 150; In acetonitrile; at 40 ℃; for 16h; pH=7.8; Inert atmosphere; Enzymatic reaction; Aqueous phosphate buffer; With citric acid; In water; acetonitrile; pH=3.96; Product distribution / selectivity;	99.42 % ee
With Candida antarctica lipase B; In aq. phosphate buffer; acetonitrile; Inert atmosphere; Large scale; Enzymatic reaction;	1.318 kg

Yield

(R/S)-ethyl 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate; With water; recombinant yeast Lipase B Candida antarctica immobilized on Immobead 150; In acetonitrile; at 40 ℃; for 16h; pH=7.8; Inert atmosphere; Enzymatic reaction; Aqueous phosphate buffer;

With citric acid; In water; acetonitrile; pH=3.96; Product distribution / selectivity;

99.42 % ee

With Candida antarctica lipase B; In aq. phosphate buffer; acetonitrile; Inert atmosphere; Large scale; Enzymatic reaction;

1.318 kg

: 1206123-55-8
2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid

: 1206123-51-4
(S)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid

: 1206123-37-6
[(3R)-7-{[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy}-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid